

Luigi Ricciardi

CEO of Menarini Biomarkers Singapore (MBS) since 2015.



*Former Director, Industry and Business Development Department, the [Singapore Immunology Network \(SIgN\)](#), A*STAR,*

He has obtained his Degree in Nuclear Engineering from Pisa University (Italy) and MBA from Luigi Bocconi University in Milano (Italy). He has worked in MNCs and SMEs, in R&D, technology transfer to cost control, planning, project management, project financing and up to general manager.

He has served as CEO and Chairman in several SMEs. In 1995, he created Newco, Biopolo srl, dedicated to the development of Biotech Industry in Italy. In particular, Biopolo's main achievements included 1) Creation of 3 start-ups from Milano University: Molecularart, Pharmeste, Sekmed 2) Feasibility study and transformation of 4 MNC's Research Laboratories into independent companies through MBO. Two of these companies were listed on Nuovo Mercato in Milano in 2000 and two on Zurich Stock Exchange in 2005. 3) Involved in the creation of Zambon Incubator of 12,000 square meters in Milano and the Centre of Excellence for Industrial Biotechnology at Bicocca University.

From 2007 to 2014, he started and managed, as Director, the Industrial Development Group (IDG) at A*STAR Biomedical Research Council, Singapore.